Leroy Shervington - Search Results

Year	Number of Results
2005	1
2007	2
2008	3
2009	2
2010	1
2011	2
2013	2
2015	1
2018	1
2020	1
2022	1
2024	0

1

Identifying Reliable Diagnostic/Predictive Biomarkers for Rheumatoid Arthritis.

Shervington L, Darekar A, Shaikh M, Mathews R, Shervington A. Shervington L, et al. Biomark Insights. 2018 Sep 24;13:1177271918801005. doi: 10.1177/1177271918801005. eCollection 2018. Biomark Insights. 2018. PMID: 30262983 Free PMC article.

2

The complexity of identifying cancer stem cell biomarkers.

Khan Z, Shervington A, Munje C, Shervington L. Khan Z, et al. Among authors: shervington l. Cancer Invest. 2013 Jul;31(6):404-11. doi: 10.3109/07357907.2013.802800. Epub 2013 Jun 11. Cancer Invest. 2013. PMID: 23758188

3

Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC.

Shervington LA, Ingham O. Shervington LA, et al. Molecules. 2022 May 5;27(9):2958. doi: 10.3390/molecules27092958. Molecules. 2022. PMID: 35566308 Free PMC article.

4

Telomerase downregulation in cancer brain stem cell.

Shervington A, Lu C, Patel R, Shervington L. Shervington A, et al. Among authors: shervington l. Mol Cell Biochem. 2009 Nov;331(1-2):153-9. doi: 10.1007/s11010-009-0153-y. Epub 2009 May 9. Mol Cell Biochem. 2009. PMID: 19430894

5

Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma.

Patel R, Shervington L, Lea R, Shervington A. Patel R, et al. Among authors: shervington l. Brain Res. 2008 Jan 10;1188:173-81. doi: 10.1016/j.brainres.2007.10.043. Epub 2007 Oct 26. Brain Res. 2008. PMID: 18021753

6

Could the Anti-Chaperone VER155008 Replace Temozolomide for Glioma Treatment.

Shervington L, Patil H, Shervington A. Shervington L, et al. J Cancer. 2015 Jul 4;6(8):786-94. doi: 10.7150/jca.12251. eCollection 2015. J Cancer. 2015. PMID: 26185541 Free PMC article.

7

Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma.

Shervington A, Patel R, Lu C, Cruickshanks N, Lea R, Roberts G, Dawson T, Shervington L. Shervington A, et al. Among authors: shervington l. Brain Res. 2007 Feb 23;1134(1):45-52. doi: 10.1016/j.brainres.2006.11.093. Epub 2007 Jan 2. Brain Res. 2007. PMID: 17196947

8

A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression.

Shervington L, Ingham O, Shervington A. Shervington L, et al. RSC Adv. 2020 May 6;10(30):17561-17570. doi: 10.1039/d0ra02686g. eCollection 2020 May 5. RSC Adv. 2020. PMID: 35515578 Free PMC article.

9

A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a.

Mehta A, Shervington L, Munje C, Shervington A. Mehta A, et al. Among authors: shervington l. Cancers (Basel). 2011 Dec 8;3(4):4228-44. doi: 10.3390/cancers3044228. Cancers (Basel). 2011. PMID: 24213135 Free PMC article.

10

Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?

Cruickshanks N, Shervington L, Patel R, Munje C, Thakkar D, Shervington A. Cruickshanks N, et al. Among authors: shervington l. Cancer Invest. 2010 Jul;28(6):608-14. doi: 10.3109/07357901003630967. Cancer Invest. 2010. PMID: 20210521

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

15 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year